C-X-C Motif Chemokine 10 Contributes to the Development of Neuropathic Pain by Increasing the Permeability of the Blood–Spinal Cord Barrier

Hao-Ling Li¹,²†, Yan Huang¹,³†, Ya-Lan Zhou², Run-Hua Teng¹, Shu-Zhuan Zhou², Jia-Piao Lin¹, Yan Yang¹, Sheng-Mei Zhu¹, Hua Xu⁵* and Yong-Xing Yao¹*¹

¹ Department of Anesthesia, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, ² Department of Anesthesia, Shanghai Hospital, Second Military Medical University, Shanghai, China, ³ Department of Anesthesia, The Central Hospital of Lishui City, Lishui, China, ⁴ Centre for Neuroscience, Zhejiang University School of Medicine, Hangzhou, China, ⁵ Department of Anesthesia, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Neuropathic pain is among the most debilitating forms of chronic pain. Studies have suggested that chronic pain pathogenesis involves neuroimmune interactions and blood–spinal cord barrier (BSCB) disruption. However, the underlying mechanisms are poorly understood. We modeled neuropathic pain in rats by inducing chronic constriction injury (CCI) of the sciatic nerve and analyzed the effects on C-X-C motif chemokine 10 (CXCL10)/CXCR3 activation, BSCB permeability, and immune cell migration from the circulation into the spinal cord. We detected CXCR3 expression in spinal neurons and observed that CCI induced CXCL10/CXCR3 activation, BSCB disruption, and mechanical hyperalgesia. CCI-induced BSCB disruption enabled circulating T cells to migrate into the spinal parenchyma. Intrathecal administration of an anti-CXCL10 antibody not only attenuated CCI-induced hyperalgesia, but also reduced BSCB permeability, suggesting that CXCL10 acts as a key regulator of BSCB integrity. Moreover, T cell migration may play a critical role in the neuroimmune interactions involved in the pathogenesis of CCI-induced neuropathic pain. Our results highlight CXCL10 as a new potential drug target for the treatment of nerve injury–induced neuropathic pain.

Keywords: neuropathic pain, chronic constriction injury, blood–spinal cord barrier, neuroinflammation, behavior, C-X-C motif chemokine 10

INTRODUCTION

Neuropathic pain is caused by primary lesions or dysfunction in the nervous system, and it is among the most debilitating forms of chronic pain (1). Its etiology is poorly understood, and this hinders the development of therapeutic and preventative strategies (2–4). One thing that is clear is that peripheral nerve injury leads to neuropathic pain by triggering radical changes that affect multiple components of the pain signaling pathway (5, 6).

Over the past decade, inflammatory responses after nerve injury have become an important topic in neuropathic pain research, and recent evidence suggests that neuroimmune interactions
are involved in the pathogenesis of chronic pain states (7–9). Accumulating evidence indicates that multiple proinflammatory mediators are released from injured nerve fibers and adjacent immune cells after nerve injury and that these mediators in turn promote central sensitization and behavioral hyperalgesia (5, 10). Furthermore, animal studies have shown that peripheral nerve injury induces circulating immune cells to enter the spinal cord parenchyma, a phenomenon that may contribute to pain-related behaviors during the development of neuropathic pain (11–13).

Because the blood–spinal cord barrier (BSCB) is the main structure regulating interactions between the immune system and the central nervous system (CNS), it is reasonable to speculate that BSCB dysfunction may play a critical role in the migration of circulating immune cells into the spinal cord (14). However, little is known about the functional states of the BSCB in the context of peripheral nerve injury–induced neuropathic pain. Researchers do not know how, or even whether, a remote injury can affect BSCB integrity. The potential consequences of compromised BSCB integrity in terms of spinal cord homeostasis and the development of pathological pain are also unclear.

This matter may be illuminated through research into chemokines, a family of small cytokines (i.e., signaling proteins) that are upregulated by primary proinflammatory mediators and tumor necrosis factors (15, 16). In the CNS, chemokines regulate myriad functions including neuronal development, synaptic transmission, and neuroinflammation (17–20). Recent studies have shown that the C-X-C motif chemokine receptor 3 (CXCR3) and its ligand C-X-C motif chemokine 10 (CXCL10) are involved in the pathophysiology of allergic itches and neuropathic pain (21–23). However, the mechanism by which CXCL10/CXCR3 signaling mediates neuropathic pain remains poorly understood.

Past studies have reported that CXCL10 promotes the entry of peripheral immune cells into the spinal cord (24, 25). On the other hand, some studies and our recent report have shown that T cell infiltration of the dorsal horn may contribute to the onset of neuropathic and inflammatory hyperalgesia (11, 12, 26, 27). However, it is unknown whether these processes contribute to hyperalgesia following peripheral nerve injury.

In this study, we examined the integrity of the BSCB and the migration of circulating immune cells into the spinal cord after chronic constriction injury (CCI) of the sciatic nerve, which induces neuropathic pain. We also examined the activation of the CXCL10/CXCR3 signaling pathway after CCI. We aimed to elucidate the pathophysiology underlying nerve injury-induced neuropathic pain and to identify potential drug targets for the treatment of neuropathic pain.

**MATERIALS AND METHODS**

**Ethics**

All animal experiments were conducted in accordance with the ARRIVE guidelines (28) and all relevant Chinese laws. The experimental protocol was approved by the Research Ethics Committee of the First Affiliated Hospital at Zhejiang University. All measures were taken to minimize the animals’ suffering and to reduce the number of animals used.

**Animals**

Adult male Sprague–Dawley rats (87 rats in total, 8 weeks at arrival) weighing 200–300 g were obtained from the Animal Center of the Chinese Academy of Sciences. They were housed in groups (4 rats/cage) in a temperature-controlled room (22 ± 2°C) with a 12-/12-h light/dark cycle and ad libitum access to food and water.

**CCI Induction**

The rats were randomly divided into the sham surgery and CCI groups (n = 5–6 per group for the behavioral test; n = 3–4 for the others). After the baseline was determined, the rats underwent the corresponding procedures on experimental day 0. CCI was surgically induced as described in our previous publication (29) and another study (30). In brief, the rats were anesthetized with intraperitoneal pentobarbital injections (60 mg/kg), and the left sciatic nerve was exposed and isolated. Three ligations were placed around the nerve with 4–0 chromic gut sutures (Pudong Jinghuan Co. Ltd., Shanghai, China). A hindpaw twitch indicated successful nerve constriction. The muscles and skin overlying the sciatic nerve were then closed with sutures. The sham surgery was identical except for the omission of sciatic nerve ligation. All animals received hydromycin penicillin injections (0.5 mL/rat; 96 mg/mL) to reduce the risk of infection. To reduce variability, all surgeries were performed by a single proficient investigator.

**Immunohistochemistry**

The rats were anesthetized with an intraperitoneal injection of pentobarbital (60 mg/kg) and perfused with normal saline (NS), followed by 4% ice-cold paraformaldehyde in phosphate buffer. The lumbar 4–5 segments were removed, post-fixed, and dehydrated in 30% sucrose at 4°C for 24 h. The samples were then incubated overnight at −20°C for cryosectioning. Cryosections were sectioned and rehydrated in 10% TBS for 30 min. The sections were incubated for 48–72 h with the following primary antibodies: mouse anti-CXCR3 (1:100 dilution, Santa Cruz Biotechnology, Dallas, TX, USA), rabbit anti-Iba1 (1:1400; Abcam, Cambridge, UK), rabbit anti-GFAP (1:500; Proteintech, Rosemont, IL, USA), and rabbit anti-NeuN (1:400, Cell Signaling Technology, Danvers, MA, USA). Subsequently, the sections were incubated with an appropriate secondary antibody (FITC–conjugated goat anti-rabbit or Cy3-conjugated goat anti-mouse; both 1:200 dilution; Beyotime, Shanghai, China) for 2 h at room temperature in the dark. Fluorescence signals were observed using a fluorescence microscope with appropriate filters.

**Western Blotting**

After the intraperitoneal injection of an overdose of pentobarbital, the spinal dorsal horn segments (lumbar 4–5) were dissected rapidly and stored in liquid nitrogen. Frozen samples were homogenized in lysis buffer containing PMSF (Beyotime). After centrifugation at 10,600 rpm and 4°C for 15 min, the supernatants were collected as protein samples. Sample aliquots containing equal amounts of protein were separated via SDS-PAGE and transferred onto polyvinylidene
Anti-CXCL10 Antibody Administration and Timeline of the Experiments

To investigate the role of CXCL10/CXCR3 signaling in CCI-induced neuropathic pain, rats were randomly divided into the sham surgery (n = 5–6) and CCI groups. Subgroups of rats that underwent CCI were selected to receive intrathecal antibody or saline injections (n = 5). Intrathecal administration was performed by lumbar puncture, as described in a previous study (31). The rats were anesthetized with isoflurane (0.3 mL/rat, Baxter International Inc.; Shanghai, China) in a home-made anesthesia box and placed on a plexiglass tube to broaden the intervertebral spaces. A 20-µL volume of normal saline or a solution containing an anti-CXCL10 antibody (200 ng/rat, Proteintech) was injected into the subarachnoid space between the L5 and L6 vertebrae with a 30-gauge needle. An instantaneous and rapid tail-flick indicated a successful puncture.

To determine the effect of CXCL10/CXCR3 signaling on the development of hyperalgesia, the first injection of anti-CXCL10 antibody was administered on experimental day 1 after CCI. Daily follow-up injections were performed until day 14 (for the behavioral experiment), unless the rats were sacrificed earlier for a BSCB permeability evaluation or flow cytometry assay. To determine the effect on established hyperalgesia, the injections were administered on experimental days 5–7 after CCI. Rats that received normal saline injections are herein referred to as the CCI + NS group, while those that received anti-CXCL10 antibody injections are herein referred to as the CCI + anti-CXCL10 antibody group.

Von Frey Test for Hypersensitivity to Mechanical Stimulation

Hyperalgesia was assessed based on paw withdrawal responses to a calibrated series of von Frey filaments (Stoelting; Wood Dale, IL, USA) as described in one of our earlier publications (32). In brief, the rats were individually placed in a chamber (20 cm × 10 cm × 20 cm) in which the floor was a customized platform consisting of a grid of iron wires with 10-mm spacings between wires. The rats were allowed to acclimate to the chamber for ≥30 min before the experiment began. A series of von Frey filaments with ascending buckling forces were applied to the midplantar surface of the hindpaw ipsilateral to the site of the CCI or sham surgery (herein referred to as the ipsilateral hindpaw) and the hindpaw contralateral to the surgical site (herein referred to as the contralateral hindpaw). Each von Frey filament was held for 2 s, and the interval between filament applications was 15 s. A brisk withdrawal or flinching of the hindpaw upon filament application was regarded as a positive response, and the filament applications continued until a filament produced positive responses in at least three out of five consecutive applications. The paw withdrawal threshold (PWT) was defined as the buckling force (in grams) of that particular filament.

PWT testing was performed by an investigator who was blinded to the rats’ group assignments. Daily PWT testing began on experimental day 0 (baseline) and continued until day 14 after CCI or sham surgery.

BSCB Permeability Evaluations

BSCB permeability was assessed with the micromolecular tracer dye sodium fluorescein (NaFlu; molecular weight, 376 g/mol; Sigma-Aldrich; St. Louis, MO, USA) according to a modified version of a published procedure (33). In brief, subgroups of rats that underwent sham or CCI surgeries were selected to receive intravenous injections of a 10% NaFlu solution (2 µL per gram of body weight) on experimental day 3. After an intraperitoneal injection of pentobarbital (60 mg/kg), NaFlu was allowed to circulate for 30 min, and the rats’ bodies were then intracardially perfused with cold saline to remove intravascular NaFlu. The L4 and L5 spinal cord segments were removed and used for subsequent analyses aimed at quantifying the amount of NaFlu extravasated from circulation.

After being weighed, the spinal cord samples were homogenized in 1 mL of phosphate-buffered saline (PBS), and a volume of 60% trichloracetic acid equal to that of the resulting solution was added to precipitate proteins. After being vortexed for 2 min, the samples were cooled for 30 min and centrifuged at 14,000 × g for 10 min. The NaFlu concentration in the supernatant was measured with a spectrophotofluorometer (excitation wavelength, 440 nm; emission wavelength, 525 nm). A calibration curve was created by assaying solutions with controlled NaFlu concentrations under identical assay conditions. All experimental measurements were within the detection range established with the calibration curve, which had an R²-value of 0.85–0.90. NaFlu levels were calculated as micrograms per gram of spinal cord tissue.

Flow Cytometry

To assess T cell entry into the spinal cord after CCI, flow cytometry was used to measure CD3-positivity levels in mononuclear cells extracted from the dorsal horn, as CD3 is a well-known T cell marker (34). On day 3 of CCI, after an overdose intraperitoneal injection of urethane (2 g/kg), the rats’ lumbar spinal cord segments were harvested. The dorsal horn tissues ipsilateral to the site of CCI or sham surgery were isolated, placed in 0.01-M PBS, and homogenized into single-cell suspensions with a cell strainer. Homogenates were washed with 0.01-M PBS, suspended in a 30%/70% discontinuous-gradient Percoll solution (Sigma-Aldrich), and centrifuged at 390 × g for 30 min.
Mononuclear cells were collected, washed with 0.01-M PBS, and resuspended in a fluorescence-activated cell sorting buffer solution for 30 min at 4°C. The cells were labeled with fluorescein isothiocyanate–conjugated mouse anti-CD3 antibodies (1:100 dilution; eBioscience, San Diego, CA, USA) for 20 min at room temperature, and ≥10,000-cell samples were analyzed with the FACSCalibur platform running with CellQuest software (Becton Dickinson; Franklin Lakes, NJ, USA) to determine the percentage of mononuclear cells that were CD3-positive.

**Statistical Analyses**

Statistical analyses were performed with Prism 5.0 software (GraphPad Software; La Jolla, CA, USA). Data were expressed as means ± standard errors. Behavioral data were analyzed with two-way repeated-measures analysis of variance (ANOVA) followed by Bonferroni post-hoc testing. BSCB permeability evaluation and flow cytometry data were analyzed with the independent t-test. Mann–Whitney U-test was used if equal-variance assumptions were not made. Statistical significance was defined as p < 0.05.

**RESULTS**

**Colocalization of CXCR3 With Spinal Neurons**

We initially performed immunohistochemistry for specific cell markers to determine the profile of CXCR3 expression in the spinal cord. The results revealed that CXCR3 is expressed abundantly in the spinal cord, where it colocalized with NeuN (neuron marker), but not with GFAP (astrocyte marker) or Iba1 (microglia marker; Figure 1).

**Effects of CCI on PWTs and BSCB Permeability**

Relative to the sham surgery group rats, the CCI group rats had decreased ipsilateral hindpaw PWTs on experimental days 3, 5, 7, 10, and 14 (p < 0.001; n = 6, ANOVA, Figure 2A), indicating CCI-induced mechanical hyperalgesia. No significant between-group differences were observed for contralateral hindpaw PWTs (Figure 2A). The CCI group rats also had dramatically elevated lumbar spinal cord NaFlu concentrations on experimental day 3 (p = 0.029; n = 6, Mann–Whitney U-test, Figure 2B), which suggests that CCI increased BSCB permeability.

**Effects of CCI on CXCL10/CXCR3 Signaling Activation**

Compared to the sham surgery group, we observed increased CXCL10 expression in the ipsilateral spinal cord after CCI injury (p = 0.003; n = 3, independent t-test, Figure 3A). The immunohistochemical results revealed that CCI induced CXCR3 activation, as shown in Figure 3B. This was further confirmed by western blotting, which demonstrated that the CXCR3 protein level was increased from 3 to 7 days after CCI (p < 0.01; n = 3, ANOVA, Figure 3C).

**Effects of CXCL10/CXCR3 Signaling Blockade on CCI-Induced Hyperalgesia**

Relative to the rats treated with CCI + saline group, rats in the CCI + anti-CXCL10 antibody group exhibited a marked increase in PWTs from experimental day 1 to day 14 or from day 5 to 7 (p < 0.05, n = 5, ANOVA, Figures 4A,B). This indicates that the anti-CXCL10 antibody attenuated CCI-induced mechanical hyperalgesia in both the developmental and established stages. On the other hand, anti-CXCL10 antibody dramatically reduced NaFlu concentrations in the lumbar spinal cord on experimental day 3 (p = 0.0049; n = 6, independent t-test, Figure 4C). These results suggest that the CXCL10/CXCR3 signaling pathway is involved in the pathophysiology of CCI-induced hypernociception and increased BSCB permeability.

**T Cell Entry Into the Spinal Cord After CCI**

The percentage of ipsilateral dorsal horn mononuclear cells that were CD3-positive was more than two times higher in the CCI group rats than in the sham surgery group rats (p < 0.0014; n = 3–4, independent t-test, Figures 5A,B) and was lower in the CCI + anti-CXCL10 antibodies group rats than in the CCI + NS group rats (p < 0.0264; n = 3, independent t-test, Figures 5B,C). These results suggest that CCI promotes T cell entry into the spinal cord, and that blocking the CXCL10/CXCR3 signaling pathway counteracts this effect, which provides further evidence for the CXCL10/CXCR3 signaling pathway being involved in the pathophysiology of CCI-induced BSCB disruption (Figure 5D).

**DISCUSSION**

In this study, we investigated the putative link between CXCL10/CXCR3 signaling-mediated BSCB disruption and neuropathic pain. As in our previous studies, CCI group rats exhibited robust post-operative behavioral hypersensitivity to mechanical stimuli, and this hypersensitivity persisted throughout the experimental period (29, 32). We also determined that CCI induced CXCL10/CXCR3 signaling, increased BSCB permeability, and promoted T cell migration into the spinal dorsal horn. Moreover, intrathecal administration of anti-CXCL10 antibodies attenuated the rats’ behavioral hyperalgesia and reduced the CCI-induced increases in BSCB permeability and T cell infiltration into the dorsal horn. To the best of our knowledge, it is the first study to report that blocking CXCL10/CXCR3 signaling attenuates the increases in BSCB permeability and T cell infiltration of the spinal cord induced by peripheral nerve injury.

Researchers have attempted to unravel the mechanisms underlying CCI-induced inflammatory reactions in the spinal cord, and have made considerable progress (35, 36). Myriad inflammatory mediators in the spinal cord may contribute to the development of neuropathic pain, with interleukin-6, tumor necrosis factor alpha, and C-X-C motif chemokines being...
FIGURE 1 | Expression and colocalization of CXCR3 with spinal neuron markers. Spinal CXCR3 is expressed abundantly in the spinal dorsal horn, where it colocalizes with NeuN (neuron marker), but not with GFAP (astrocyte marker) or Iba1 (microglia marker). The last row presents enlargements of the areas in white frames. Scale bar = 100 µm. NeuN, neuronal nuclear antigen; GFAP, glial fibrillary acidic protein; Iba1, ionized calcium binding adapter molecule.

The chemokines CXCL9, CXCL10, and CXCL11 compose a subfamily of chemokines that bind to CXCR3 and have various roles in nociceptive signaling. Past investigations have suggested that CXCL10/CXCR3 signaling contributes to the pathophysiology of neuropathic pain, although spinal CXCL9 and CXCL11 levels do not seem to have important roles in the development of chronic pain (42, 43). Other reports have shown that T cell infiltration of the dorsal horn may contribute to the onset of neuropathic and inflammatory hyperalgesia (10, 12, 39). Our present findings further this line of research by elucidating...
FIGURE 2 | CCI resulted in behavioral hyperalgesia and BSCB disruption. (A) PWTs of hindpaws ipsilateral and contralateral to surgical sites in the sham surgery group and CCI group rats on various experimental days (**p < 0.001; ANOVA, n = 6). (B) Lumbar spinal cord NaFlu concentrations in the sham surgery group and CCI group rats on experimental day 3 (***p < 0.05; Mann–Whitney U-test, n = 4). The data are shown as means ± standard errors. ANOVA, analysis of variance; BSCB, blood-spinal cord barrier; Contra, contralateral; CCI, chronic constriction injury; Ips, ipsilateral; NaFlu, sodium fluorescein; PWT, paw withdrawal threshold.

FIGURE 3 | CCI induces CXCL10/CXCR3 signaling activation. (A) Upregulated CXCL10 expression is observed in the ipsilateral spinal cord after CCI injury (**p < 0.01; independent t-test, n = 3). (B) Immunohistochemistry reveals the CCI-mediated induction of CXCR3 activation. (C) The spinal CXCR3 protein level increased during days 3–7 after CCI as shown by western blotting (**p < 0.01; ***p < 0.001; ANOVA, n = 3). The data are presented as means ± standard errors. GAPDH was used as a loading control. ANOVA, analysis of variance; CCI, chronic constriction injury; CXCL10, C-X-C motif chemokine 10; Contra, contralateral to CCI.

FIGURE 4 | Neutralizing CXCL10 alleviated hyperalgesia and reduced CCI-induced BSCB disruption. (A,B) Hindpaw PWTs in CCI + anti-CXCL10 antibodies group and CCI + saline group rats on various experimental days (*p < 0.05, **p < 0.01, ***p < 0.001; ANOVA, n = 5–6). (C) Lumbar spinal cord NaFlu concentrations in the CCI + anti-CXCL10 antibodies group, CCI + saline group, and sham surgery group rats on experimental day 3 (**p < 0.01, CCI + NS group vs. sham surgery group; Mann–Whitney U-test, n = 4–6; #p < 0.01, CCI + anti-CXCL10 antibodies group vs. CCI + NS group; independent t-test, n = 6). The data are shown as means ± standard errors. ANOVA, analysis of variance; BSCB, blood-spinal cord barrier; CCI, chronic constriction injury; CXCL10, C-X-C motif chemokine 10; NaFlu, sodium fluorescein; PWT, paw withdrawal threshold; NS, normal saline.
the potential mechanistic role of CXCL10/CXCR3 signaling in the development of neuropathic pain following peripheral nerve injury. Our observation that blocking CXCL10/CXCR3 signaling reduced CCI-induced T cell migration into the spinal cord is consistent with past reports suggesting that CXCL10/CXCR3 signaling plays a role in the migration of T cells from the periphery into the CNS (44).

Within the spinal cord, neurons, and glia can secrete CXCL10, which in turn promotes the entry of circulating immune cells into the spinal cord (45–48). Studies have shown that type 1 T helper cells secrete interferon gamma, and elevated spinal cord interferon gamma levels can induce CXCL10 secretion. CXCL10 in turn increases BSCB permeability and promotes the migration of T cells into the spinal cord (44, 49). This creates a positive feedback system that favors ever-increasing migration of activated T cells into the spinal cord. This implies that blocking the contribution of CXCL10/CXCR3 signaling to increased BSCB permeability, as we did by administering anti-CXCL10 antibodies to the CCI group rats, may disrupt this positive feedback loop.

In conclusion, our study suggests that CXCL10/CXCR3 signaling triggers a positive feedback loop involving BSCB permeabilization and T lymphocyte infiltration of the spinal cord. Intrathecal administration of anti-CXCL10 antibodies prevents the development of CCI-induced neuropathic pain. Our findings highlight the CXCL10/CXCR3 signaling pathway as a new potential target for drugs designed to treat chronic pain.

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT

The animal study was reviewed and approved by Research Ethics Committee of the First Affiliated Hospital at Zhejiang University.
AUTHOR CONTRIBUTIONS
H-LL, Y-XY, and HX contributed to the conception and design of the study. H-LL and YH performed the statistical analyses. H-LL wrote the first draft of the manuscript. S-MZ wrote sections of the manuscript. All authors contributed to manuscript revisions and read and approved the submitted version.

REFERENCES
1. Jensen TS, Baron R, Haanpaa M, Kalso E, Loeser JD, Rice ASC, et al. A new definition of neuropathic pain. Pain. (2011) 152:2204–5. doi: 10.1016/j.pain.2011.06.017
2. Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson A, Yarnitsky D, et al. Neuropathic pain. Nat Rev Dis Primers. (2017) 3:17002. doi: 10.1038/nrdp.2017.2
3. Zhao JY, Liang LL, Gu XY, Li ZS, Sun LL, et al. DNA methyltransferase DNMT3a contributes to neuropathic pain by repressing Kcna2 in primary afferent neurons. Nat Commun. (2017) 8:14712. doi: 10.1038/ncomms14712
4. Hayward JH, Lee SJ. A decade of research on TLR2 discovering its pivotal role in glial activation and neuroinflammation in neurodegenerative diseases. Expe Neurobiol. (2014) 23:133–47. doi: 10.5607/en.2014.23.2.138
5. Scholz J, Woof CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. (2007) 10:1361–8. doi: 10.1038/nrn1992
6. Inoue K, Tsuda M. Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential. Nat Rev Neurosci. (2018) 19:138–52. doi: 10.1038/s41583-018-0082-4
7. Grace PM, Rolan PE, Hutchinson MR. Peripheral immune contributions to the maintenance of central glial activation underlying neuropathic pain. Brain Behav Immun. (2011) 25:1322–32. doi: 10.1016/j.bbi.2011.04.003
8. Yang Y, Li H, Li TT, Luo H, Gu XY, Lu N, et al. Delayed activation of spinal microglia contributes to the maintenance of bone cancer pain in female Wistar rats via P2X7 receptor and IL-18. J Neurosci. (2015) 35:7950–63. doi: 10.1523/JNEUROSCI.2520-14.2015
9. Huh Y, Ji RR, Chen G. Neuroinflammation, bone marrow stem cells, and chronic pain. Front Immunol. (2017) 8:1014. doi: 10.3389/fimmu.2017.01014
10. Petrovic J, Silva JR, Bannerman CA, Dickenson A, Yarnitsky D, et al. T-Cell infiltration and signaling in the adult dorsal spinal cord is a mechanism that contributes to the transition from acute to chronic mechanical allodynia after adult rat tibial nerve injuries. J Neuroimmunol. (2017) 309:454–63. doi: 10.1016/j.jneuroim.2017.06.015
11. Costigan M, Moss A, Latremoliere A, Johnston C, Verma-Gandhu M, Herbert TA, et al. T-Cell infiltration and signaling in the adult dorsal spinal cord is a major contributor to neuropathic pain-like hypersensitivity. J Neurosci. (2009) 29:14415–22. doi: 10.1523/JNEUROSCI.4569-09.2009
12. Cao L, DeLeo JA. CNS-infiltrating CD4+ T lymphocytes contribute to murine spinal nerve transection-induced neuropathic pain. Eur J Immunol. (2008) 38:4484–58. doi: 10.1002/eji.200737485
13. Bartanusz V, Iezova D, Alajajian B, Digicaylioglu M. The blood-splinal cord barrier: morphology and clinical implications. Ann Neurol. (2010) 77:194–406. doi: 10.1002/ana.22421
14. Lian Q, Yu SL, Yin CQ, Zhu B, Chen Z, Meng ZZ, et al. Plasma IFN-gamma-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma. Pancreatol. (2019) 19:340–5. doi: 10.1016/j.pan.2019.01.015
15. Blanchet X, Langer M, Weber C, Koenen RR, von Hundenhausen P. Touch of chemokines. Front Immunol. (2012) 3:175. doi: 10.3389/fimmu.2012.00175
16. Shou J, Peng J, Zhao Z, Huang X, Li H, Li L, et al. CCL26 and CCR3 are associated with the acute inflammatory response in the CNS in experimental autoimmune encephalomyelitis. J Neuroimmunol. (2019) 333:576967. doi: 10.1016/j.jneuroim.2019.576967
17. Skinner D, Marro BS, Lane TE. Chemokine CXCL10 and coronavirus-induced neurologic disease. Viral Immunol. (2019) 32:25–37. doi: 10.1089/vim.2018.0073
18. Nash B, Meucci O. Functions of the chemokine receptor CXCXR4 in the central nervous system and its regulation by mu-opioid receptors. Int Rev Neurobiol. (2014) 118:105–28. doi: 10.1016/B978-0-12-801284-0.00005-1
19. Semple BD, Kossmann T, Morganti-Kossmann MC. Role of chemokines in CNS health and pathology: a focus on the CCL2/CXCR2 and CXCL8/CXCR2 networks. J Cerebr Blood Flow Met. (2010) 30:459–73. doi: 10.1038/jcbfm.2009.240
20. Qu LT, Fu K, Shimada SG, LaMotte RH. CCR-7 channel is required for CXCL10-induced neuronal activation and itch response in a murine model of allergic contact dermatitis. J Neurophysiol. (2017) 118:619–24. doi: 10.1152/jn.00187.2017
21. Xu WT, Liu WH, Yu W. The involvement of iron responsive element (-) divalent metal transporter 1-mediated the spinal iron overload via CXCL10/CXCR3 pathway in neuropathic pain in rats. Neurosci Lett. (2019) 694:154–60. doi: 10.1016/j.neulet.2018.12.001
22. Backryd E, Lind AL, Thulin M, Larsson A, Gerdel B, Gordh T. High levels of cerebrospinal fluid chemokines point to the presence of neuroinflammation in peripheral neuropathic pain: a cross-sectional study of 2 cohorts of patients compared with healthy controls. Pain. (2017) 158:2487–95. doi: 10.1097/j.pain.0000000000001061
23. Mansfield KL, Johnson N, Nunez A, Hicks D, Jackson AC, Fooks AR. Up-regulation of chemokine gene transcripts and T-cell infiltration into the central nervous system and dorsal root ganglia are characteristics of experimental European bat lyssavirus type 2 infection of mice. J Neurovirol. (2008) 14:218–28. doi: 10.1080/13550280802008297
24. Ryu JK, Petersen MA, Murray SG, Baeten KM, Meyer-Franke A, Chan JP, et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat Commun. (2015) 6:8164. doi: 10.1038/ncomms9164
25. Du B, Ding YQ, Xiao X, Ren HY, Su BY, Qi JG. CD4+ αβ T cell infiltration into the leptomeninges of lumbar dorsal roots contributes to the transition from acute to chronic mechanical allodynia after adult rat tibial nerve injuries. J Neuroinflammation. (2018) 15:81. doi: 10.1186/s12974-018-1115-7
26. Zhou YL, Zhou SZ, Li HL, Hu ML, Li H, Guo QH, et al. Bidirectional modulation between infiltrating CD3+ T lymphocytes and astrocytes in the spinal cord drives the development of allostERIC rats. Sci Rep. (2018) 8:151. doi: 10.1038/s41598-017-18357-z
27. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. (2010) 160:1577–9. doi: 10.1111/j.1476-5381.2010.00872.x
28. Huang LE, Guo SH, Thitsersane L, Yang Y, Zhou YF, Yao YX. N-methyl-D-aspartate receptor subtype 2B antagonist, Ro 25-6981, attenuates neuropathic pain by inhibiting postsynaptic density 95 expression. Sci. Rep. (2018) 8:7848. doi: 10.1038/s41598-018-26209-7
29. Bennett GJ, Xie YX, A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. (1988) 33:87–107. doi: 10.1016/0304-3959(88)90209-6

FUNDING
This work received grants from the National Natural Science Foundation of China (Grant Nos. 81471127, 81600954, and 816005213).

ACKNOWLEDGMENTS
The authors would like to thank Editage (www.editage.com) for English language editing.
31. Sun S, Chen WL, Wang PF, Zhao ZQ, Zhang YQ. Disruption of glial function enhances electroacupuncture analgesia in arthritic rats. *Exp Neurol.* (2006) 198:294–302. doi: 10.1016/j.expneurol.2005.11.011

32. Lin JP, Chen CQ, Huang LE, Li NN, Yang Y, Zhu SM, et al. Morphological and functional changes of blood-brain barrier in kindled rats with cortical dysplasia. *Brain Res.* (2008) 1208:181–91. doi: 10.1016/j.brainres.2008.02.101

33. Kaya M, Gurses C, Kalayci R, Ekizoglu O, Ahishali B, Orhan N, et al. Central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. *J Neurosci.* (2018) 28:5189–94. doi: 10.1523/JNEUROSCI.02154-14

34. Ellis A, Bennett DLH. Neuroinflammation and the generation of neuropathic pain. *Br J Anaesthesia.* (2014) 112:72. doi: 10.1093/bja/aet128

35. Skaper SD, Facci L, Zusso M, Giusti P. An inflammation-centric view of neurological disease: beyond the neuron. *Front Cell Neurosci.* (2018) 12:72. doi: 10.3389/fncel.2018.00072

36. Chai Q, She R, Huang Y, Fu ZF. Expression of neuronal CXCL10 induced by rabies virus infection initiates infiltration of inflammatory cells, production of chemokines/cytokines and enhancement of blood-brain barrier permeability. *J Virol.* (2015) 89:870–6. doi: 10.1128/JVI.02154-14

37. Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of peripheral nerve injury in the living mouse. *Mol Pain.* (2014) 10:60. doi: 10.1186/1744-8069-10-60

38. Bu H, Shu B, Gao F, Liu C, Guan X, Ke C, et al. Spinal IFN-gamma-induced protein-10 (CXCL10) mediates metastatic breast cancer-induced bone pain by activation of microglia in rat models. *Breast cancer Res Treat.* (2014) 143:255–63. doi: 10.1007/s10549-013-2807-4

39. Jiang BC, He LN, Wu XB, Shi H, Zhang WW, Zhang ZJ, et al. Promoted interaction of C/EBPalpha with demethylated Cxcr3 gene promoter contributes to neuropathic pain in mice. *J Neurosci.* (2017) 37:685–706. doi: 10.1523/JNEUROSCI.2262-16.2016

40. Oh JW, Schwiebert LM, Benveniste EN. Cytokine regulation of CC and CXC chemokine expression by human astrocytes. *J Neurovirol.* (1999) 5:82–94. doi: 10.3109/13550289909029749

41. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. *Autoimmun. Rev.* (2014) 13:272–80. doi: 10.1016/j.autrev.2013.10.010

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Li, Huang, Zhou, Tong, Zhou, Lin, Yang, Zhu, Xu and Yao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.